ENDPOINTS

AstraZeneca reports Phase 3 win for hypoparathyroidism drug eneboparatide

AstraZeneca’s $1.05 billion bet on French biotech Amolyt Pharma seems to be paying off. On Monday, the UK drugmaker reported a late-stage success for the hypoparathyroidism drug that sparked the acquisition deal between the companies ...

Mar 17, 2025 - 17:52
 0
AstraZeneca reports Phase 3 win for hypoparathyroidism drug eneboparatide
AstraZeneca’s $1.05 billion bet on French biotech Amolyt Pharma seems to be paying off. On Monday, the UK drugmaker reported a late-stage success for the hypoparathyroidism drug that sparked the acquisition deal between the companies ...
Read More

Tags:

Previous Article

Hera Swings Past Mars, Sees Deimos From a New Angle

Next Article

Should Kids Do Chores?

Related Posts

Supernus’ stock sinks after placebo effect derails mid-stage depression study

Supernus’ stock sinks after placebo effect derails mid-...

Feb 19, 2025  0

#ASCOGU: Pfizer’s prostate cancer data leak shows promising results in early-stage study

#ASCOGU: Pfizer’s prostate cancer data leak shows promi...

Feb 11, 2025  0

Bavarian Nordic CEO says reshoring manufacturing to the US can take years

Bavarian Nordic CEO says reshoring manufacturing to the...

Mar 5, 2025  0